AR042193A1 - Composiciones farmaceuticas que tienen un vehiculo modificado - Google Patents

Composiciones farmaceuticas que tienen un vehiculo modificado

Info

Publication number
AR042193A1
AR042193A1 ARP030104227A ARP030104227A AR042193A1 AR 042193 A1 AR042193 A1 AR 042193A1 AR P030104227 A ARP030104227 A AR P030104227A AR P030104227 A ARP030104227 A AR P030104227A AR 042193 A1 AR042193 A1 AR 042193A1
Authority
AR
Argentina
Prior art keywords
composition
liquid excipient
modified
unmodified
composition according
Prior art date
Application number
ARP030104227A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR042193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR042193A1 publication Critical patent/AR042193A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Composición que comprende: (a) uno a tres agentes bioactivos; y (b) un vehículo que comprende: (i) un excipiente líquido modificado, y (ii) un excipiente líquido no modificado en la que la relación en volumen del excipiente líquido modificado a excipiente no modificado es entre 0,00001:99,99999 y menos que 0,01:99,99, que proporciona la composición con propiedades de liberación sostenida predecibles, y en la que inmediatamente después de fabricar la composición, dicha composición se puede administrar a un receptor de forma que los uno a tres agentes bioactivos son liberados en el receptor de una forma sostenida. Reivindicación 3: La composición de acuerdo con la reivindicación 2, caracterizada porque dicha sustancia bioactiva comprende el ácido libre de ceftiofur cristalino. Reivindicación 7: La composición de acuerdo con la reivindicación 4, caracterizada porque dicho excipiente líquido modificado comprende aceite de semilla de algodón modificado. Reivindicación 8: La composición de acuerdo con la reivindicación 4, caracterizada porque dicho excipiente líquido no modificado comprende aceite de coco.
ARP030104227A 2002-11-19 2003-11-17 Composiciones farmaceuticas que tienen un vehiculo modificado AR042193A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42768002P 2002-11-19 2002-11-19

Publications (1)

Publication Number Publication Date
AR042193A1 true AR042193A1 (es) 2005-06-15

Family

ID=32326579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104227A AR042193A1 (es) 2002-11-19 2003-11-17 Composiciones farmaceuticas que tienen un vehiculo modificado

Country Status (18)

Country Link
US (1) US7659061B2 (es)
EP (1) EP1569693B1 (es)
JP (1) JP4656945B2 (es)
KR (1) KR20050085037A (es)
CN (2) CN103272243A (es)
AR (1) AR042193A1 (es)
AU (1) AU2003276594B2 (es)
BR (1) BR0316310A (es)
CA (1) CA2502025C (es)
IL (1) IL168183A (es)
MX (1) MXPA05005319A (es)
NO (1) NO20051688L (es)
NZ (1) NZ539923A (es)
PL (1) PL377740A1 (es)
RU (1) RU2401127C2 (es)
TW (1) TWI267379B (es)
WO (1) WO2004045646A1 (es)
ZA (1) ZA200503040B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
CN104039369B (zh) 2011-07-20 2017-06-16 布莱阿姆青年大学 疏水性塞拉集宁化合物和包含该化合物的装置
EP2755661A1 (en) 2011-09-13 2014-07-23 Brigham Young University Compositions for treating bone diseases and broken bones
BR112014005914B1 (pt) 2011-09-13 2021-11-09 Brigham Young University Produtos para cicatrização de feridas tecidulares
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
KR20140116111A (ko) 2011-12-21 2014-10-01 브라이엄 영 유니버시티 구강 관리 조성물
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
CA2888259C (en) 2012-10-17 2019-05-28 Brigham Young University Treatment and prevention of mastitis
CN105451742B (zh) 2013-01-07 2021-04-06 布莱阿姆青年大学 减少细胞增殖和治疗某些疾病的方法
JP6518230B2 (ja) 2013-03-15 2019-05-22 ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍ Ｙｏｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 炎症、自己免疫疾患、および疼痛を治療する方法
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US110561A (en) * 1870-12-27 Improvement in children s carriages
US4297353A (en) 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
JP2856444B2 (ja) * 1989-07-28 1999-02-10 呉羽化学工業株式会社 ビタミンｄ▲下３▼代謝産物製剤
JP3078859B2 (ja) 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
FR2692480B1 (fr) 1992-06-22 1995-12-08 Technico Flor Sa Nouvelles compositions cosmetiques ou alimentaires renfermant du copaiba.
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
DE4340879A1 (de) 1993-12-01 1995-06-08 Horst P O Dr Wolf Arzneimittel zur Behandlung der Herzinsuffizienz
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
JP2000512649A (ja) 1996-06-27 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 徐放性スフェンタニル組成物
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
JP2004508418A (ja) 2000-09-12 2004-03-18 ファルマシア・アンド・アップジョン・カンパニー 特定の水分活性を持つ医薬組成物
PT1317256E (pt) * 2000-09-12 2008-12-17 Pharmacia & Upjohn Co Llc Composição farmacêutica com veículo modificado

Also Published As

Publication number Publication date
US20040170650A1 (en) 2004-09-02
CA2502025C (en) 2013-07-02
TW200427466A (en) 2004-12-16
NO20051688D0 (no) 2005-04-05
RU2401127C2 (ru) 2010-10-10
RU2005115131A (ru) 2005-10-27
JP2006514629A (ja) 2006-05-11
CN1713923A (zh) 2005-12-28
JP4656945B2 (ja) 2011-03-23
WO2004045646A1 (en) 2004-06-03
CA2502025A1 (en) 2004-06-03
PL377740A1 (pl) 2006-02-20
EP1569693A1 (en) 2005-09-07
EP1569693B1 (en) 2016-12-28
KR20050085037A (ko) 2005-08-29
NO20051688L (no) 2005-08-02
US7659061B2 (en) 2010-02-09
MXPA05005319A (es) 2005-07-25
NZ539923A (en) 2007-02-23
IL168183A (en) 2010-04-29
AU2003276594B2 (en) 2009-01-08
ZA200503040B (en) 2006-09-27
BR0316310A (pt) 2005-09-27
CN103272243A (zh) 2013-09-04
TWI267379B (en) 2006-12-01
AU2003276594A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
AR042193A1 (es) Composiciones farmaceuticas que tienen un vehiculo modificado
PE20070583A1 (es) Formulacion que comprende un inhibidor de dipeptidil-peptidasa iv y metformina
CR7921A (es) Formulaciones farmaceuticas liquidas de palonosetron
AR111679A2 (es) Formulación farmacéutica de liberación controlada, procesos, usos, método
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
PA8565501A1 (es) Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas
AR040154A1 (es) Articulo absorbente
PE20030733A1 (es) Composiciones de goma de mascar y confiteria con composiciones de agente que elimina manchas encapsulado y procedimientos para su fabricacion y uso
AR045699A1 (es) Derivados de triazolopirimidinas como inhibidores de sintasa quinasa 3 de glucogeno
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20060372A1 (es) Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
CL2009001560A1 (es) Composición nutricional para bebes que comprende una mezcla de oligosacáridos compuesta de oligosacáridos n-acetilados, galactooligosácaridos y oligosacáridos sialilados; y su uso.
CL2013003554A1 (es) Forma de dosificación farmacéutica sólida en forma de dispersión o solución sólida que comprende ritonavir, entre 50-80% en peso de al menos un polímero soluble en agua con una tg de al menos 50 °c, respecto del peso total de la forma de dosificación, y un tensoactivo (divisional de la sol.1844-2009 y esta divisional de la sol. 393-2006).
AR054382A1 (es) Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso
AR109263A2 (es) Composición que comprende moxidectina
PE20070588A1 (es) Formas de presentacion farmaceuticas solidas de administracion oral con liberacion rapida del principio activo
SG155880A1 (en) Multiparticulates of preferably an opioid, and method of manufacturing using extrusion
NZ599594A (en) Fast dissolving solid dosage form
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
AR049920A1 (es) Composiciones para el cuidado bucal
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
AR029826A1 (es) Una composicion de sabor y el procedimiento para prepararla
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal